DelveInsight’s comprehensive “Myelodysplastic Syndrome Pipeline Insights 2025” report delivers extensive analysis of more than 120 pharmaceutical companies and over 150 investigational drugs currently in the Myelodysplastic Syndrome development pipeline. The report encompasses detailed profiles of Myelodysplastic Syndrome treatment candidates spanning both clinical and preclinical development phases. Additionally, it includes thorough evaluation of Myelodysplastic Syndrome therapeutics organized by product classification, developmental stage, administration method, and molecular structure. The report also identifies dormant pipeline candidates in this therapeutic space.
Access our extensive report now to examine clinical-stage advancements and strategic partnerships revolutionizing the sector! @ Myelodysplastic Syndrome Pipeline Outlook Report
Major Highlights from the Myelodysplastic Syndrome Pipeline Analysis
- On October 30, 2025, Takeda launched an investigation to determine how effectively elritercept performs in decreasing the requirement for RBC transfusions. Additional objectives include learning how to successfully elritercept functions in minimizing the need for RBC transfusions across extended timeframes or in adults with elevated transfusion requirements. The investigation will also monitor elritercept’s safety profile and tolerability.
- On October 23, 2025, Agios Pharmaceuticals initiated an investigation to establish proof of concept of tebapivat in participants with LR-MDS in Phase 2a and to assess the impact of tebapivat on transfusion independence (TI) in participants with LR-MDS in phase 2b.
- DelveInsight’s Myelodysplastic Syndrome pipeline analysis reveals a dynamic landscape featuring over 120 active pharmaceutical developers advancing more than 150 investigational treatments for Myelodysplastic Syndrome.
- Key Myelodysplastic Syndrome developers include Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, Agios Pharmaceuticals, AbbVie, Daiichi Sankyo Company, Geron Corporation, Astex Pharmaceuticals, Jazz Pharmaceuticals, Maxinovel Pty., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd., BeiGene, Ellipses Pharma, Treadwell Therapeutics, Bellicum Pharmaceuticals, among others.
- Notable Myelodysplastic Syndrome treatment candidates comprise Deferasirox, Bortezomib, Decitabine and cedazuridine, Luspatercept, Epoetin Alfa, among others.
Discover how prominent Myelodysplastic Syndrome Companies are strategically positioning themselves for achievement in the evolving pharmaceutical landscape—access the complete report now!” @ Myelodysplastic Syndrome Clinical Trials Assessment
Understanding Myelodysplastic Syndrome
Myelodysplastic syndrome (MDS) represents a heterogeneous collection of hematologic neoplasms traditionally characterized as a clonal disorder of hematopoietic stem cells resulting in dysplasia and ineffective hematopoiesis in the bone marrow. Some individuals with MDS may experience a transformation into acute myeloid leukemia (AML). MDS is typically diagnosed in older individuals over the age of 65. Clinical presentations include a reduction in the quantity of red blood cells (RBC), platelets, and white blood cells (WBC). The disease progression is variable.
Myelodysplastic Syndrome Investigational Drug Profiles
Tamibarotene: Syros Pharmaceuticals
Tamibarotene (previously SY-1425) represents an oral selective retinoic acid receptor alpha (RAR) agonist. The organization is developing treatments for genomically defined patient subsets whose disease is distinguished by the overexpression of the RARA gene. Approximately 50% of MDS individuals and 30% of AML individuals have RARA overexpression. When RAR is expressed beyond its strictly controlled natural ligand, cells in the bone marrow may fail to differentiate into healthy myeloid cells, which can result in hematological malignancies. However, when oral tamibarotene is administered, tamibarotene binds to RAR, enabling the restoration of gene expression and myeloid differentiation. The organization currently investigates tamibarotene in the Phase III SELECT-MDS-1 trial in newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) individuals with RARA overexpression.
RVU120: Ryvu Therapeutics
RVU120 (SEL120) represents a specific, selective inhibitor of CDK8 and its paralog, CDK19. Preclinical investigations demonstrated the robust antileukemic potential of RVU120, which was frequently associated with the multilineage commitment of CD34+ AML cells. Furthermore, RVU120 could enhance proliferation and stimulate erythroid differentiation of CD34+ cells obtained from Diamond-Blackfan anemia (DBA) individuals. Presently, the drug undergoes Phase II evaluation for Myelodysplastic syndromes treatment.
Emavusertib: Curis
Emavusertib, which is being advanced by Curis, represents a small-molecule IRAK4 kinase inhibitor. Inhibition of IRAK4-L activity with emavusertib (CA-4948) prevents leukemic growth in non-clinical experiments. Because IRAK4 serves a central function in this pathway, it is regarded as an attractive target for the creation of therapeutics to treat these B-cell malignancies as well as certain inflammatory conditions. As part of the partnership with Aurigene, in October 2015, Curis exclusively licensed a program of orally available, small molecule inhibitors of IRAK4 kinase, including emavusertib (CA-4948). Presently, the drug undergoes Phase I/II evaluation for Myelodysplastic syndromes treatment.
MNV-201: Minovia Therapeutics
MNV-201 represents an investigational cell therapy created by Minovia Therapeutics, targeting low-risk Myelodysplastic Syndromes (MDS). It employs a novel strategy known as Mitochondrial Augmentation Technology (MAT), which involves enriching a patient’s own hematopoietic stem and progenitor cells (HSPCs) with mitochondria obtained from allogeneic placental sources. This therapy seeks to address mitochondrial dysfunction, which is involved in the pathophysiology of MDS. Currently, MNV-201 undergoes a Phase I clinical trial (NCT06465160) that is actively enrolling participants. The investigation’s primary objective is to evaluate the safety profile and therapeutic effects of MNV-201 in individuals diagnosed with low-risk MDS.
Key Insights from the Myelodysplastic Syndrome Pipeline Report
The report delivers comprehensive information regarding:
- Pharmaceutical companies developing treatments for Myelodysplastic Syndrome management with aggregate therapeutic candidates created by each organization for the same.
- Multiple investigational candidates organized across early-phase, mid-phase, and late-phase development for Myelodysplastic Syndrome therapy.
- Myelodysplastic Syndrome pharmaceutical companies pursue targeted therapeutic development, including both active and inactive (suspended or terminated) programs.
- Myelodysplastic Syndrome investigational drugs categorized by development phase, administration route, target receptor, monotherapy versus combination therapy, mechanism of action, and molecular classification.
- In-depth examination of partnerships (pharmaceutical-pharmaceutical and pharmaceutical-academic collaborations), licensing arrangements, and funding details for future Myelodysplastic Syndrome market progression.
From early-phase research to late-phase Myelodysplastic Syndrome Clinical Trials, our evaluation covers key organizations, innovative therapeutic approaches, and the next generation of Emerging Drugs—Access now! @ Myelodysplastic Syndrome Treatment Drugs
Myelodysplastic Syndrome Pharmaceutical Companies
Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, Agios Pharmaceuticals, AbbVie, Daiichi Sankyo Company, Geron Corporation, Astex Pharmaceuticals, Jazz Pharmaceuticals, Maxinovel Pty., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd., BeiGene, Ellipses Pharma, Treadwell Therapeutics, Bellicum Pharmaceuticals, among others.
Myelodysplastic Syndrome Pipeline Report: Therapeutic Classification by Administration Route
Investigational products have been organized under multiple administration routes including:
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Myelodysplastic Syndrome Products: Molecular Classification
Candidates have been grouped under various molecular categories including:
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Stay informed with the most recent Myelodysplastic Syndrome Pipeline Insights! @ Myelodysplastic Syndrome Market Drivers and Barriers, and Future Perspectives
Report Scope
- Coverage: Global
- Myelodysplastic Syndrome Pharmaceutical Companies: Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, Agios Pharmaceuticals, AbbVie, Daiichi Sankyo Company, Geron Corporation, Astex Pharmaceuticals, Jazz Pharmaceuticals, Maxinovel Pty., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd., BeiGene, Ellipses Pharma, Treadwell Therapeutics, Bellicum Pharmaceuticals, among others.
- Myelodysplastic Syndrome Investigational Therapies: Deferasirox, Bortezomib, Decitabine and cedazuridine, Luspatercept, Epoetin Alfa, among others.
- Myelodysplastic Syndrome Therapeutic Classification by Product Type: Mono, Combination, Mono/Combination
- Myelodysplastic Syndrome Therapeutic Classification by Clinical Phases: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Explore comprehensive insights for novel drugs for Myelodysplastic Syndrome Treatment, visit @ Myelodysplastic Syndrome Drugs
Report Contents
* Introduction
* Executive Summary
* Myelodysplastic Syndrome: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Myelodysplastic Syndrome- DelveInsight’s Analytical Perspective
* Late Stage Products (Phase III)
* Tamibarotene: Syros Pharmaceuticals
* Mid Stage Products (Phase II)
* CA-4948: Curis
* Early Stage Products (Phase I)
* MNV-201: Minovia Therapeutics
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Inactive Products
* Myelodysplastic Syndrome Key Companies
* Myelodysplastic Syndrome Key Products
* Myelodysplastic Syndrome- Unmet Needs
* Myelodysplastic Syndrome- Market Drivers and Barriers
* Myelodysplastic Syndrome- Future Perspectives and Conclusion
* Myelodysplastic Syndrome Analyst Views
* Myelodysplastic Syndrome Key Companies
* Appendix
About Us
DelveInsight represents a premier healthcare-focused market research and advisory firm delivering superior market intelligence and strategic analysis to support evidence-based business decisions. Supported by seasoned industry specialists and comprehensive understanding of life sciences and healthcare industries, we deliver tailored research solutions and strategic insights to international clients. Engage with us to obtain superior, precise, and current intelligence for maintaining competitive advantage.
Contact Us
Kanishk
kkumar@delveinsight.com